

Yingyao Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4057005/publications.pdf>

Version: 2024-02-01

60
papers

1,018
citations

687220

13
h-index

477173

29
g-index

61
all docs

61
docs citations

61
times ranked

1553
citing authors

#	ARTICLE	IF	CITATIONS
1	Health technology assessment and economic evaluation: Is it applicable for the traditional medicine?. Integrative Medicine Research, 2022, 11, 100756.	0.7	11
2	Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with Traditional Chinese Medicine in China. Patient Preference and Adherence, 2022, Volume 16, 297-306.	0.8	3
3	Using economic evaluations to support acupuncture reimbursement decisions: current evidence and gaps. BMJ, The, 2022, 376, e067477.	3.0	7
4	Cost-effectiveness of stereotactic body radiotherapy in the treatment of non-small-cell lung cancer (NSCLC): a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, , 1-12.	0.7	2
5	Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome with Constipation in China. Advances in Therapy, 2022, 39, 2971-2983.	1.3	1
6	Tackling brain drain at Chinese CDCs: understanding job preferences of public health doctoral students using a discrete choice experiment survey. Human Resources for Health, 2022, 20, .	1.1	5
7	A Study of Patient Preferences for the Treatment of Non-small Cell Lung Cancer in Western China: A Discrete-Choice Experiment. Frontiers in Public Health, 2021, 9, 653450.	1.3	2
8	Physical Activity and Glycemic Control Status in Chinese Patients with Type 2 Diabetes: A Secondary Analysis of a Randomized Controlled Trial. International Journal of Environmental Research and Public Health, 2021, 18, 4292.	1.2	2
9	True cost of surgical aortic valve replacement and implications for price setting and diagnosis-related groups: evidence from a tertiary hospital in Eastern China. Journal of Comparative Effectiveness Research, 2021, 10, 697-708.	0.6	2
10	Hospitalization Costs of COVID-19 Cases and Their Associated Factors in Guangdong, China: A Cross-Sectional Study. Frontiers in Medicine, 2021, 8, 655231.	1.2	11
11	Research capacity of global health institutions in China: a gap analysis focusing on their collaboration with other low-income and middle-income countries. BMJ Global Health, 2021, 6, e005607.	2.0	5
12	What Are the Important Factors Influencing the Recruitment and Retention of Doctoral Students in a Public Health Setting? A Discrete Choice Experiment Survey in China. International Journal of Environmental Research and Public Health, 2021, 18, 9474.	1.2	4
13	Cost-Effectiveness of Flash Glucose Monitoring for the Management of Patients with Type 1 and Patients with Type 2 Diabetes in China. Diabetes Therapy, 2021, 12, 3079-3092.	1.2	9
14	What Is Valued Most by Patients With Type 2 Diabetes Mellitus When Selecting Second-Line Antihyperglycemic Medications in China. Frontiers in Pharmacology, 2021, 12, 802897.	1.6	1
15	Physician-patient shared decision making, patient satisfaction, and adoption of new health technology in China. International Journal of Technology Assessment in Health Care, 2020, 36, 518-524.	0.2	4
16	Factors Influencing Medication Non-Adherence among Chinese Older Adults with Diabetes Mellitus. International Journal of Environmental Research and Public Health, 2020, 17, 6012.	1.2	8
17	Physicians' perception toward non-invasive prenatal testing through the eye of the Rogers' diffusion of innovation theory in China. International Journal of Technology Assessment in Health Care, 2020, 36, 239-244.	0.2	2
18	Health literacy and exercise interventions on clinical outcomes in Chinese patients with diabetes: a propensity score-matched comparison. BMJ Open Diabetes Research and Care, 2020, 8, e001179.	1.2	4

#	ARTICLE	IF	CITATIONS
19	EQ-5D-3L Decrements by Diabetes Complications and Comorbidities in China. <i>Diabetes Therapy</i> , 2020, 11, 939-950.	1.2	18
20	Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments. <i>BMJ Open</i> , 2020, 10, e032336.	0.8	10
21	Health equity and COVID-19: global perspectives. <i>International Journal for Equity in Health</i> , 2020, 19, 104.	1.5	442
22	Effects of different mark-up drug policies on drug-related expenditures in tertiary public hospitals: an interrupted time series study in Shanghai, China, 2015-2018. <i>BioScience Trends</i> , 2020, 14, 16-22.	1.1	10
23	Barriers of effective health insurance coverage for rural-to-urban migrant workers in China: a systematic review and policy gap analysis. <i>BMC Public Health</i> , 2020, 20, 408.	1.2	40
24	Building a People-Centred Integrated Care Model in Urban China: A Qualitative Study of the Health Reform in Luohu. <i>International Journal of Integrated Care</i> , 2020, 20, 9.	0.1	13
25	Mapping of Health Technology Assessment in China: Situation Analysis and International Comparison. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 401-407.	0.2	7
26	<p>Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1701-1709.	0.8	16
27	Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. <i>Journal of Medical Economics</i> , 2019, 22, 336-343.	1.0	19
28	Overseeing health care facilities in Shanghai, China: regulatory regime, activities and challenges of the governmental regulatory system. <i>International Journal for Equity in Health</i> , 2019, 18, 75.	1.5	0
29	Cost-Effectiveness Analysis of Non-invasive Prenatal Testing for Down Syndrome in China. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 237-242.	0.2	11
30	Cost-Effectiveness of Cryoballoon Ablation Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation in China: Results Based on Real-World Data. <i>Value in Health</i> , 2019, 22, 863-870.	0.1	7
31	Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List. <i>BMC Health Services Research</i> , 2019, 19, 112.	0.9	4
32	Health literacy and exercise-focused interventions on clinical measurements in Chinese diabetes patients: A cluster randomized controlled trial. <i>EClinicalMedicine</i> , 2019, 17, 100211.	3.2	15
33	Determinants of efficiency growth of county-level public hospitals-evidence from Chongqing, China. <i>BMC Health Services Research</i> , 2019, 19, 858.	0.9	14
34	Hospital efficiency and utilization of high-technology medical equipment: A panel data analysis. <i>Health Policy and Technology</i> , 2018, 7, 65-72.	1.3	27
35	OP126 Shared Decision-Making Influences Patientsâ€™ Adoption Of Stents In China. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 48-49.	0.2	0
36	PP135 Cost-Effectiveness Of Cryoballoon Ablation In China: Real-World Results. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 119-119.	0.2	0

#	ARTICLE	IF	CITATIONS
37	PP39 Health Technology Assessment And Aging: Moving Evidence To Action. International Journal of Technology Assessment in Health Care, 2018, 34, 80-80.	0.2	0
38	Equity assessment of the distribution of CT and MRI scanners in China: a panel data analysis. International Journal for Equity in Health, 2018, 17, 157.	1.5	29
39	AGING AND HEALTH TECHNOLOGY ASSESSMENT: AN IDEA WHOSE TIME HAS COME. International Journal of Technology Assessment in Health Care, 2018, 34, 442-446.	0.2	7
40	Development of health technology assessment in China: New challenges. BioScience Trends, 2018, 12, 102-108.	1.1	28
41	Determinants of knowledge translation from health technology assessment to policy-making in China: From the perspective of researchers. PLoS ONE, 2018, 13, e0190732.	1.1	13
42	Systematic review and meta-analysis of non-invasive prenatal DNA testing for trisomy 21: implications for implementation in China. Prenatal Diagnosis, 2017, 37, 864-873.	1.1	13
43	INTEGRATE-HTA: A LOW- AND MIDDLE-INCOME COUNTRY PERSPECTIVE. International Journal of Technology Assessment in Health Care, 2017, 33, 599-604.	0.2	11
44	Effect of health literacy and exercise interventions on glycated haemoglobin levels in Chinese patients with type 2 diabetes: a cluster-randomised controlled trial. Lancet, The, 2017, 390, S92.	6.3	0
45	Health technology assessment in China: challenges and opportunities. Global Health Journal (Amsterdam, Netherlands), 2017, 1, 11-20.	1.9	7
46	OP42 Cost-Benefit Of Computed Tomography In Secondary Hospitals In China. International Journal of Technology Assessment in Health Care, 2017, 33, 19-19.	0.2	0
47	Individual nursing care for the elderly among China's aging population. BioScience Trends, 2017, 11, 694-696.	1.1	10
48	Perceptions of health technology assessment knowledge translation in China: a qualitative study on HTA researchers and policy-makers. International Journal of Healthcare Technology and Management, 2017, 16, 44.	0.1	3
49	Preparing for the introduction of hospital autonomy in Laos: an assessment of current situation and suggestions for policy-making. International Journal of Health Planning and Management, 2016, 31, 148-166.	0.7	3
50	How patients think about social responsibility of public hospitals in China?. BMC Health Services Research, 2016, 16, 371.	0.9	11
51	Harnessing China's universities for global health. Lancet, The, 2016, 388, 1860-1862.	6.3	9
52	Factors associated with utilization of maternal serum screening for Down syndrome in mainland China: a cross-sectional study. BMC Health Services Research, 2015, 16, 8.	0.9	6
53	Improved self-management skills in Chinese diabetes patients through a comprehensive health literacy strategy: study protocol of a cluster randomized controlled trial. Trials, 2014, 15, 498.	0.7	17
54	DIFFERENCES IN EVALUATING HEALTH TECHNOLOGY ASSESSMENT KNOWLEDGE TRANSLATION BY RESEARCHERS AND POLICY MAKERS IN CHINA. International Journal of Technology Assessment in Health Care, 2014, 30, 612-620.	0.2	11

#	ARTICLE	IF	CITATIONS
55	Health technology assessment development in China. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 202-209.	0.2	34
56	Preliminary study into the economic burden of Down syndrome in China. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2008, 82, 25-33.	1.6	20
57	Issues in Drug Pricing, Reimbursement, and Access in China with References to Other Asia-Pacific Region. <i>Value in Health</i> , 2008, 11, S124-S129.	0.1	34
58	Use of genetic services for the prevention and control of birth defects in China. <i>International Journal of Healthcare Technology and Management</i> , 2007, 8, 451.	0.1	1
59	Cost-effectiveness analysis of prenatal diagnosis intervention for Down's syndrome in China. <i>International Journal of Technology Assessment in Health Care</i> , 2007, 23, 138-145.	0.2	15
60	Volatility of the pharmaceutical market in China and the USA. <i>International Journal of Healthcare Technology and Management</i> , 2006, 7, 541.	0.1	0